Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5263260 | 1.00 | EPHX1 (0.41) | EPHX1ATMPOLBEPHX2SMYD3 | |
| SCHEMBL31366709 | 0.89 | EPHX1 (0.56) | EPHX1EPHX2MMP2MMP8NPC1 | |
| SCHEMBL30034737 | 0.89 | EPHX1 (0.52) | EPHX1ATMEPHX2MMP2MMP8 | |
| SCHEMBL30035740 | 0.87 | EPHX1 (0.59) | EPHX1EPHX2MMP2MMP8NPC1 | |
| SCHEMBL23573302 | 0.81 | EPHX1 (0.57) | EPHX1EPHX2NPC1MAPTRAB9A | |
| SCHEMBL21378960 | 0.81 | POLB (0.48) | EPHX1ATMPOLBEPHX2SMYD3 | |
| SCHEMBL425737 | 0.80 | — | — | |
| SCHEMBL6816984 | 0.79 | MMP2 (0.40) | EPHX1POLBEPHX2SMYD3MMP2 | |
| SCHEMBL6823717 | 0.79 | MMP2 (0.40) | EPHX1POLBEPHX2SMYD3MMP2 | |
| SCHEMBL19692400 | 0.78 | MTNR1A (0.39) | EPHX1SMYD3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399443-B1 | NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2007-12-12 | — | — | EP | disclosed |
| US-20070135422-A1 | Nitrogen-containing bicycle heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135422-A1 | Nitrogen-containing bicycle heterocycles for use as antibacterials | NRDC, NUCB2, NISCH | EPHX1 4021/4885ATM 3601/4885POLB 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.